A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies Including DLBCL

Collins, GP; Townsend, W; Abdulgawad, A; Namburi, S; Williams, A; DosReis, AFP; Krebs, MG; Evans, J; Blagden, SP; Plummer, R; Hochhauser, D; Sharp, A; Cole, G; Rogers, S; Chan, D; Whelan, S; El-Sharkawi, D

BLOOD, 2023; 142 ():

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索